Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Glaukos

Analyst Scoreboard: 5 Ratings For Glaukos

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Glaukos (NYSE:GKOS) in the last three months.

Benzinga's Top Ratings Upgrades, Downgrades For October 4, 2022

Benzinga's Top Ratings Upgrades, Downgrades For October 4, 2022

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6 or PF-06760805 for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy. Pfizer shares traded in a…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Glaukos Stock Scores Rising Price Performance With Jump To 91 RS Rating

Glaukos shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ:MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. MediWound shares traded in a range of $1.6 to $1.76 on a day…

Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022

Glaukos: Q4 Earnings Insights

Glaukos (NYSE:GKOS) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Glaukos beat estimated earnings by 16.22%, reporting an EPS of $-0.31 versus an estimate of $-0.37.

inkl

Read news from The Economist, FT, and more,
with one subscription

Analyst Ratings For Glaukos

Analyst Ratings For Glaukos

Glaukos (NYSE:GKOS) has observed the following analyst ratings within the last quarter:

Organisations

European Commission

American Express

Southwest Airlines

Paramount Global

SherwinWilliams

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Prostate Cancer

Ulcerative Colitis

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play